Artivion, Inc.
NYSE:AORTMedical - Devices
-$0.11 today
- Market cap
- $904.56M
- Beta
- 1.26
- P/E (TTM)
- 86.7
- EPS (TTM)
- $0.24
Volume 0.91M
Average 0.64M
AORT Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Artivion, Inc.NYSE: AORT
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables declines year over year
Q1 FY2026 accounts receivables of $2.76M (cash outflow) fell 65.2% year over year, ahead of the -89.5% change in trailing-twelve-month accounts receivables. Sequentially, it fell 56.5% from the prior quarter. Over 3 fiscal years it compounded at -18.3% a year.
Context
- Accounts receivables amounted to 1.6% of revenue in FY2025, down 2.3 pp from a year earlier.
- Accounts receivables grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -65.2% holds above the trailing-twelve-month pace of -89.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (7.27M) USD
- Year-over-year change
- +52.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.27M) | +52.8% |
| FY2024 | 2024-12-31 | (15.4M) | -280.1% |
| FY2023 | 2023-12-31 | (4.05M) | +69.6% |
| FY2022 | 2022-12-31 | (13.34M) | -15.4% |
| FY2021 | 2021-12-31 | (11.56M) | — |
Accounts Receivables vs competitors
How AORT compares with its peers on the latest reported figures
- AORT's LTM Mar 2026 accounts receivables of $2.11M is the 10th largest of the 11 companies compared; the peer median is $4.99M.
- Its year-over-year change of -89.5% is the 9th highest of 10, against a peer median of +159.0%.
- Accounts receivables amounts to 0.5% of revenue for AORT, versus a peer median of 2.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $129.93M | +1833.7% | +193.7% | 28.8% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $89.9M | +276.1% | — | 1.4% |
| LTM Jul 2026 | $49.25M | +31.2% | +29.4% | 2.7% | |
| LTM Jun 2026 | $34.3M | +159.0% | -1.0% | 3.8% | |
| LTM Jun 2026 | $19.37M | -48.7% | — | 1.2% | |
| LTM Mar 2026 | $18.14M | -25.4% | -56.4% | 5.6% | |
| LTM Sep 2026 | $14.92M | +202.5% | +50.6% | 0.5% | |
| LTM Mar 2026 | $14.56M | +1796.8% | +131.9% | 30.0% | |
| LTM Jun 2026 | $9.98M | -1289.6% | — | 0.7% | |
| LTM Mar 2026 | $2.11M | -89.5% | -18.3% | 0.5% | |
| LTM Jun 2026 | $0 | — | — | — | |
| Peer median (excluding AORT) | $4.99M | +159.0% | +40.0% | 2.7% | |
Competitors are the stored peer set for AORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.83M) | (19.19M) | (30.69M) | (13.36M) | 9.77M |
| Depreciation & Amortization | 23.98M | 22.44M | 23.08M | 24.21M | 22.46M |
| Deferred Income Tax | (4.47M) | (1.72M) | (1.39M) | (1.51M) | 37K |
| Stock-Based Compensation | 10.71M | 12.34M | 14.42M | 14.24M | 24.39M |
| Change in Working Capital | (33.23M) | (25.94M) | (16.19M) | (17.24M) | (22.16M) |
| Accounts Receivables | (11.56M) | (13.34M) | (4.05M) | (15.4M) | (7.27M) |
| Inventory | (18.38M) | (8.4M) | (14.36M) | (6.14M) | (15.28M) |
| Accounts Payables | (1.89M) | (1.96M) | 1.68M | 9.5M | 2.18M |
| Other Working Capital | (1.4M) | (2.23M) | 535K | (5.21M) | (1.8M) |
| Other Non-Cash Items | 15.26M | 6.91M | 29.6M | 15.9M | 3.64M |
| Operating Cash Flow | (2.59M) | (5.15M) | 18.83M | 22.24M | 38.13M |
| Capital Expenditures | (13.09M) | (10.72M) | (7.43M) | (11.19M) | (39.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 19M | 0 | 0 | 0 | 0 |
| Other Investing Activities | (249K) | 0 | 6.93M | (17M) | (3M) |
| Investing Cash Flow | 5.66M | (10.72M) | (502K) | (28.19M) | (42.04M) |
| Debt Repayment | (3.09M) | (2.75M) | (2.77M) | (358K) | (2.46M) |
| Common Stock Issued | 0 | 0 | 0 | 5.73M | 13.07M |
| Common Stock Repurchased | (1.91M) | (1.8M) | (559K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.22M) | 2.91M | 4.2M | (3.17M) | 2.42M |
| Financing Cash Flow | (12.22M) | (1.64M) | 865K | 2.2M | 13.03M |
| Effect of Forex Changes | 2.2M | 1.85M | 401K | (1.73M) | 2.32M |
| Net Change in Cash | (6.95M) | (15.66M) | 19.59M | (5.48M) | 11.45M |
| Free Cash Flow | (15.68M) | (15.87M) | 11.4M | 11.05M | (911K) |
Artivion, Inc.
NYSE:AORT
Intrinsic Alpha fair value
Locked
Current Price
$18.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.